Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients
Research article published in Therapeutics and clinical risk management (2021)
Abstract
Venous thromboembolism (VTE) is a known cause of morbidity and mortality, especially among acutely ill medical patients. Although VTE prophylaxis is part of post-discharge clinical care in surgical patients, there is controversy regarding its use in acutely ill medical patients and the current guideline statements suggest against its routine use. Recent clinical trials (APEX, MAGELLAN and MARINER) compared the safety and efficacy of direct oral anticoagulants (including betrixaban and rivaroxaban) with the standard of the care, enoxaparin, to identify the risk-benefit tradeoff. In this review, we summarized the key findings from these trials and substudies and recent updates in society guidelines regarding VTE prevention. In addition, we discussed the potential barriers, cost-effectiveness, and COVID-19 with respect to the implementation of extended-duration or post-discharge usage of direct oral anticoagulants.
Abstract sourced from PubMed (NCBI) for the cited record. See the original publication for the authoritative version.
Resumen
Peer-reviewed research on anticoagulant and antithrombotic drug development relevant to leech-derived and synthetic compounds. Indexed in PubMed and verified against the NCBI record.
Por qué esto importa para la hirudoterapia
Esta revisión resume la evidencia y el debate de las guías de las sociedades sobre el uso de anticoagulantes orales directos (como betrixaban y rivaroxaban) frente a enoxaparina para la profilaxis de VTE en pacientes médicos hospitalizados en estado crítico, basándose en los ensayos APEX, MAGELLAN y MARINER, y abordando consideraciones de rentabilidad y de COVID-19. Para ASH, proporciona contexto sobre el panorama moderno de la anticoagulación sistémica frente al cual puede comprenderse la acción localizada basada en el secretoma de la terapia con sanguijuelas medicinales. Advertencia: este artículo no contiene contenido alguno sobre sanguijuelas o hirudoterapia (el 'lee' de 'slug' es el apellido del autor, no 'sanguijuela'); se trata de una revisión narrativa de anticoagulantes farmacológicos y es relevante únicamente como antecedente general, no como evidencia de hirudoterapia.
Citación
Current Opinion on the use of Direct Oral Anticoagulants for the Prophylaxis of Venous Thromboembolism among Medical Inpatients.
Lee et al. · Therapeutics and clinical risk management, 2021
Contexto clínico relacionado
Explore cómo esta investigación se conecta con la práctica clínica
Añadido a la biblioteca ASH: May 28, 2026 · Última actualización del sitio: June 18, 2026